DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown Sells 629 Shares

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown sold 629 shares of DexCom stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total transaction of $79,411.25. Following the completion of the sale, the executive vice president now owns 68,212 shares in the company, valued at $8,611,765. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Jon Brown also recently made the following trade(s):

• On Thursday, March 28th, Michael Jon Brown sold 2,624 shares of DexCom stock. The shares were sold at an average price of $140.04, for a total transaction of $367,464.96.

DexCom Stock Performance

DXCM stock traded up $0.77 during midday trading on Thursday, reaching $126.65. 2,311,384 shares of the company were exchanged, compared to its average volume of 3,046,284. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. The business has a 50-day moving average price of $131.68 and a two-hundred day moving average price of $119.57. DexCom, Inc. has a one year low of $74.75 and a one year high of $142.00. The firm has a market capitalization of $50.37 billion, a price-to-earnings ratio of 80.84, a price-to-earnings-growth ratio of 2.18 and a beta of 1.23.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. Equities research analysts forecast that DexCom, Inc. will post 1.77 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Raymond James lifted their price objective on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Canaccord Genuity Group lifted their price objective on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday, April 26th. Citigroup lifted their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. UBS Group boosted their target price on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Finally, StockNews.com upgraded shares of DexCom from a “hold” rating to a “buy” rating in a report on Wednesday. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $141.67.

Institutional Investors Weigh In On DexCom

A number of institutional investors have recently modified their holdings of the business. Jennison Associates LLC boosted its position in shares of DexCom by 2.7% in the first quarter. Jennison Associates LLC now owns 388,302 shares of the medical device company’s stock valued at $53,858,000 after acquiring an additional 10,217 shares during the period. Daiwa Securities Group Inc. boosted its position in shares of DexCom by 8.4% in the first quarter. Daiwa Securities Group Inc. now owns 61,500 shares of the medical device company’s stock valued at $8,530,000 after acquiring an additional 4,775 shares during the period. Fidelis Capital Partners LLC bought a new stake in shares of DexCom in the first quarter valued at about $238,000. Tobam boosted its position in shares of DexCom by 16.1% in the first quarter. Tobam now owns 1,988 shares of the medical device company’s stock valued at $276,000 after acquiring an additional 275 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. boosted its position in shares of DexCom by 5.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 10,188 shares of the medical device company’s stock valued at $1,413,000 after acquiring an additional 485 shares during the period. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.